Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD) Study

The purpose of this study is to evaluate if a combination of two medications, dasatinib and quercetin (also known as “senolytics”), penetrate the brain using cerebrospinal fluid (CSF) in individuals with early Alzheimer’s disease (AD). This combination of drug therapy has been shown to affect dysregulated cells in humans with other chronic illnesses and in Alzheimer’s mouse models. We want to know if this combination of medications will reach the brain in order to evaluate if this intervention may be effective for treating AD symptoms in future studies.

Participation in the study includes completion of eleven study visits across 20 to 24 weeks. Pre- and post-treatment assessments include brain MRI, lumbar puncture, laboratory blood work and evaluations of thinking, mood and physical functioning.

Do I have to already be diagnosed with Alzheimer’s disease in order to participate?

Yes, you must have a diagnosis of Alzheimer’s disease to participate in the study. You can continue your regular prescribed medications for Alzheimer’s disease [Exelon (rivastigmine), Razadyne (galantamine), Aricept(donepezil)] while enrolled in the study.

Eligibility

  • Adults, aged 65 years or older, with a diagnosis of Alzheimer’s disease

All individuals who meet study qualifications and are enrolled in the study will receive dasatinib and quercetin.

There is no cost to participate in the study.

To learn more, contact:

Amy Saklad

Director of Research Operations

Office: 210-567-8229

Fax: 210-450-2250

saklada@uthscsa.edu